AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Several studies have reported that HDACIs can block AKT/mTOR signaling in many cancers (Kawamata, Chen, & Koeffler, 2007; Ou et al., 2015; P. Zhang et al., 2015), while the relationship between HDACI induction and AKT/mTOR pathway in CML cell remains unclear.